Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 139

1.

Cost-effectiveness of asenapine in the treatment of bipolar I disorder patients with mixed episodes.

Sawyer L, Azorin JM, Chang S, Rinciog C, Guiraud-Diawara A, Marre C, Hansen K.

J Med Econ. 2014 Jul;17(7):508-19. doi: 10.3111/13696998.2014.914030. Epub 2014 Apr 30.

PMID:
24720805
2.

Cost-effectiveness of asenapine in the treatment of patients with bipolar I disorder with mixed episodes in an Italian context.

Caresano C, Di Sciascio G, Fagiolini A, Maina G, Perugi G, Ripellino C, Vampini C.

Adv Ther. 2014 Aug;31(8):873-90. doi: 10.1007/s12325-014-0139-3. Epub 2014 Jul 24.

3.

Cost-effectiveness of asenapine in the treatment of bipolar disorder in Canada.

Lachaine J, Beauchemin C, Mathurin K, Gilbert D, Beillat M.

BMC Psychiatry. 2014 Jan 22;14:16. doi: 10.1186/1471-244X-14-16.

4.

The cost-effectiveness of lamotrigine in the maintenance treatment of adults with bipolar I disorder.

Calvert NW, Burch SP, Fu AZ, Reeves P, Thompson TR.

J Manag Care Pharm. 2006 May;12(4):322-30.

5.

Asenapine: a review of its use in the management of mania in adults with bipolar I disorder.

Chwieduk CM, Scott LJ.

CNS Drugs. 2011 Mar;25(3):251-67. doi: 10.2165/11206700-000000000-00000. Review.

PMID:
21323396
6.

Cost effectiveness of quetiapine in patients with acute bipolar depression and in maintenance treatment after an acute depressive episode.

Ekman M, Lindgren P, Miltenburger C, Meier G, Locklear JC, Chatterton ML.

Pharmacoeconomics. 2012 Jun 1;30(6):513-30. doi: 10.2165/11594930-000000000-00000.

PMID:
22591130
7.

[Antipsychotics in bipolar disorders].

Vacheron-Trystram MN, Braitman A, Cheref S, Auffray L.

Encephale. 2004 Sep-Oct;30(5):417-24. Review. French.

PMID:
15627046
8.

Effects of asenapine on depressive symptoms in patients with bipolar I disorder experiencing acute manic or mixed episodes: a post hoc analysis of two 3-week clinical trials.

Szegedi A, Zhao J, van Willigenburg A, Nations KR, Mackle M, Panagides J.

BMC Psychiatry. 2011 Jun 20;11:101. doi: 10.1186/1471-244X-11-101.

9.

A rapid and systematic review and economic evaluation of the clinical and cost-effectiveness of newer drugs for treatment of mania associated with bipolar affective disorder.

Bridle C, Palmer S, Bagnall AM, Darba J, Duffy S, Sculpher M, Riemsma R.

Health Technol Assess. 2004 May;8(19):iii-iv, 1-187. Review.

10.

Effect of asenapine on manic and depressive symptoms in bipolar I patients with mixed episodes: results from post hoc analyses.

Azorin JM, Sapin C, Weiller E.

J Affect Disord. 2013 Feb 15;145(1):62-9. doi: 10.1016/j.jad.2012.07.013. Epub 2012 Aug 4.

PMID:
22868059
11.

Efficacy and tolerability of asenapine for acute mania in bipolar I disorder: meta-analyses of randomized-controlled trials.

Vita A, De Peri L, Siracusano A, Sacchetti E; ATOM group.

Int Clin Psychopharmacol. 2013 Sep;28(5):219-27. doi: 10.1097/YIC.0b013e32836290d2.

PMID:
23719049
12.

Asenapine treatment and health-related quality of life in patients experiencing bipolar I disorder with mixed episodes: post-hoc analyses of pivotal trials.

Michalak EE, Guiraud-Diawara A, Sapin C.

Curr Med Res Opin. 2014 Apr;30(4):711-8. doi: 10.1185/03007995.2013.874988. Epub 2014 Jan 10.

PMID:
24329543
13.

Effects of asenapine in bipolar I patients meeting proxy criteria for moderate-to-severe mixed major depressive episodes: a post hoc analysis.

Berk M, Tiller JW, Zhao J, Yatham LN, Malhi GS, Weiller E.

J Clin Psychiatry. 2015 Jun;76(6):728-34. doi: 10.4088/JCP.13m08827.

14.

Asenapine for long-term treatment of bipolar disorder: a double-blind 40-week extension study.

McIntyre RS, Cohen M, Zhao J, Alphs L, Macek TA, Panagides J.

J Affect Disord. 2010 Nov;126(3):358-65. doi: 10.1016/j.jad.2010.04.005.

PMID:
20537396
15.

Asenapine in the treatment of acute mania in bipolar I disorder: a randomized, double-blind, placebo-controlled trial.

McIntyre RS, Cohen M, Zhao J, Alphs L, Macek TA, Panagides J.

J Affect Disord. 2010 Apr;122(1-2):27-38. doi: 10.1016/j.jad.2009.12.028. Epub 2010 Jan 22.

PMID:
20096936
16.

A systematic review and economic model of the clinical effectiveness and cost-effectiveness of interventions for preventing relapse in people with bipolar disorder.

Soares-Weiser K, Bravo Vergel Y, Beynon S, Dunn G, Barbieri M, Duffy S, Geddes J, Gilbody S, Palmer S, Woolacott N.

Health Technol Assess. 2007 Oct;11(39):iii-iv, ix-206. Review.

17.

Asenapine for schizophrenia and bipolar disorder: a review of the efficacy and safety profile for this newly approved sublingually absorbed second-generation antipsychotic.

Citrome L.

Int J Clin Pract. 2009 Dec;63(12):1762-84. doi: 10.1111/j.1742-1241.2009.02228.x. Epub 2009 Oct 14. Review.

PMID:
19840150
18.

A 3-week, randomized, placebo-controlled trial of asenapine in the treatment of acute mania in bipolar mania and mixed states.

McIntyre RS, Cohen M, Zhao J, Alphs L, Macek TA, Panagides J.

Bipolar Disord. 2009 Nov;11(7):673-86. doi: 10.1111/j.1399-5618.2009.00748.x. Erratum in: Bipolar Disord. 2010 May;12(3):350.

PMID:
19839993
19.

Asenapine as adjunctive treatment for acute mania associated with bipolar disorder: results of a 12-week core study and 40-week extension.

Szegedi A, Calabrese JR, Stet L, Mackle M, Zhao J, Panagides J; Apollo Study Group.

J Clin Psychopharmacol. 2012 Feb;32(1):46-55. doi: 10.1097/JCP.0b013e31823f872f.

PMID:
22198448
20.

[Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation].

Llorca PM, Miadi-Fargier H, Lançon C, Jasso Mosqueda G, Casadebaig F, Philippe A, Guillon P, Mehnert A, Omnès LF, Chicoye A, Durand-Zaleski I.

Encephale. 2005 Mar-Apr;31(2):235-46. Review. French.

PMID:
15959450
Items per page

Supplemental Content

Write to the Help Desk